




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N</p>	<p>A2</p>	<p>(11) International Publication Number: WO 99/55829 (43) International Publication Date: 4 November 1999 (04.11.99)</p>
<p>(21) International Application Number: PCT/US99/07016 (22) International Filing Date: 22 April 1999 (22.04.99) (30) Priority Data: 09/065,606 24 April 1998 (24.04.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/065,606 (CIP) Filed on 24 April 1998 (24.04.98) (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN S.P.A. [IT/IT]; Viale Pasteur, 10, I-20014 Nerviano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): SOLARI, Augusto, In-venti [IT/IT]; Via Cascina Bianca, 17/2, I-20142 Milan (IT). ZANUSO, Giovanna [IT/IT]; Via Zoja Luigi, 5, I-20100 Milan (IT). FILIPPINI, Silvia [IT/IT]; Via Elba, 30, I-20144 Milan (IT). TORTI, Francesca [IT/IT]; Corso Garibaldi, 70, I-20121 Milan (IT). OTTEN, Sharee [US/US]; 5706 Nutone Street, Madison, WI 53711 (US). COLOMBO, Anna, Luisa [IT/IT]; Via Elba, 14, I-20144 Milan (IT). HUTCHINSON,</p>		<p>Charles, R. [US/US]; 4293 South Deer Run Court, Cross Plains, WI 53528 (US). (74) Agents: MURRAY, Robert, B. et al.; Nikaido, Marmelstein, Murray & Oram LLP, Metropolitan Square, Suite 330 - G Street Lobby, 655 Fifteenth Street, N.W., Washington, DC 20005-5701 (US). (81) Designated States: CA, CN, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i></p>

(54) Title: PROCESS FOR PREPARING DOXORUBICIN



(57) Abstract

The ability to convert daunorubicin into doxorubicin can be improved by transforming a host cell with a recombinant vector comprising a DNA molecule comprising: a DNA region or fragment containing the gene *doxA* encoding daunorubicin 14-hydroxylase and a DNA region or fragment containing one or more gene conferring daunorubicin and doxorubicin resistance.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Process for Preparing Doxorubicin.

Field of the Invention

The present invention concerns a process for improving daunorubicin to
5 doxorubicin conversion by means of host cells transformed with recombinant vectors
comprising DNA encoding a daunorubicin C-14 hydroxylase together with genes
conferring resistance to anthracycline antibiotics.

Background of the Invention

Anthracyclines of daunorubicin group such as doxorubicin, carminomycin and
10 aclacinomycin and their synthetic analogs are among the most widely employed agents
in antitumoral therapy (F. Arcamone, Doxorubicin, Academic Press New York, 1981,
pp. 12; A. Grein, Process Biochem., 16:34, 1981; T. Kaneko, Chimicaoggi May 11,
1988; C. E. Myers et al., "Biochemical mechanism of tumor cell kill" in Anthracycline and
Anthracenedione-Based Anti-cancer Agents (Lown, J. W., ed.) Elsevier Amsterdam,
15 pp. 527-569, 1988; J. W. Lown, Pharmac. Ther. 60:185, 1993).

Anthracyclines of the daunorubicin group are naturally occurring compounds
produced by various strains of *Streptomyces* (*S.peucetius*, *S.coeruleorubidus*,
S.galilaeus, *S.griseus*, *S.griseoruber*, *S.insignis*, *S.viridochromogenes*, *S.bifurcus* and
S.sp. strain C5) and by *Actinomyces carminata*. Doxorubicin is mainly produced by
20 strains of *S. peucetius*. In particular daunorubicin and doxorubicin are synthesized in
Streptomyces peucetius ATCC 29050 and in *S. peucetius subsp. caesius* ATCC 27952.
The anthracycline doxorubicin is made by *S.peucetius* 27952 from malonic acid,
propionic acid and glucose by the pathway summarized in Grein, Advan. Applied
Microbiol. 32:203, 1987 and in Eckart and Wagner, J. Basic Microbiol. 28:137, 1988.
25 Aklavinone (11-deoxy- ϵ -rhodomycinone), ϵ -rhodomycinone, rhodomycin D,
carminomycin and daunorubicin are established intermediates in this process. The final
step in this pathway involves the C-14 hydroxylation of daunorubicin to doxorubicin.

Genes for daunorubicin biosynthesis have been obtained from *S.peucetius*
29050 and *S.peucetius* 27952 by cloning experiments (Stutzman-Engwall and
30 Hutchinson, Proc.Natl.Acad.Sci.USA 86:3135,1988; Otten et al., J.Bacteriol.
172:3427,1990).The gene encoding the daunorubicin 14-hydroxylase, which converts
daunorubicin to doxorubicin has been obtained from *S.peucetius* 29050 and its mutants
by cloning experiments and it was overexpressed in the host cells of *Streptomyces*
species and *Escherichia coli* as described in WO 96/27014, publication date

Sept.6,1996.

Two genes of the daunorubicin biosynthetic cluster, *drrA* and *drrB*, which confer doxorubicin and daunorubicin resistance to *Streptomyces lividans* have been cloned from *S. peucetius* ATCC 29050 strain (Guilfoile and Hutchinson, Proc.Natl.Acad.Sci.USA 88:8553, 1991) (Accession Number M73758 of Genbank) and from the *S.peucetius* 7600 mutant (EP-0371,112-A and Colombo et al., J.Bacteriol.174:1641,1992). These genes encode two translationally coupled proteins, both of which are required for daunorubicin and doxorubicin resistance in this host. The sequence of the predicted product of one of the two genes is similar to the products of other transport and resistance genes, most notably the P-glycoproteins from mammalian tumor cells. Another gene, *drrC*, which confers resistance to daunorubicin and doxorubicin with a strong sequence similarity to the *Escherichia coli* and *Micrococcus luteus* UvrA proteins involved in excision repair of DNA has been cloned from *S.peucetius* ATCC 29050 (Lomovskaya et al., J.Bacteriol.178:3238, 1996).

15 Summary of the invention

The present invention provides a process for improving daunorubicin to doxorubicin conversion in host cells by means of recombinant vectors comprising a DNA region or fragment containing the gene *dxrA* encoding daunorubicin 14-hydroxylase together with a DNA region or fragment containing one, two or three genes, selected from the group consisting of *drrA*, *drrB* and *drrC*, conferring resistance to daunorubicin and doxorubicin. The last three genes confer a high level of resistance in the host cells to doxorubicin, the product of the conversion process, making the process more efficient than the previous one obtained using host cells transformed with the recombinant vectors carrying only the DNA fragment containing the *dxrA* gene, described in WO 96/27014, even when a strong promoter is used.

The DNA of the invention comprises preferably all three of the *drrA*, *drrB* and *drrC* genes or only the two *drrA* and *drrB* genes.

The DNA may be ligated to a heterologous transcriptional control sequence in the correct fashion or cloned into a vector at the restriction site appropriately located

near a transcriptional control sequence in a vector. Typically, the vector is a plasmid. The recombinant vectors may be used to transform a suitable host cell. The host may be strains of Actinomycetes that do not or do produce anthracyclines, preferably strains of *Streptomyces*.

5 Brief description of the drawings

Fig. 1 (a-c) illustrate the construction of the plasmid pIS156 described in Example 1. This plasmid was constructed by insertion of the 2.9 kb fragment containing the *doxA* (formerly *dxrA*), the *dnrV* (formerly *dnrORF10*) and the C-terminal part of the *dnrU* (Δ *dnrU*, formerly *dnrORF9*) genes, obtained from the recombinant plasmid pIS70
10 (WO 96/27014 and A. Inventi Solari et al., GMBIM '96, P58), under the control of the strong promoter *ermE** (Bibb et al., Molec. Microbiol. 14:533, 1994) into the plasmid pWHM3 (Vara et al., J. Bacteriol. 171:5872, 1989).

In order to better describe the invention, we provide the SEQ.ID. No:1 of 2.867 nt consisting of the *doxA*, *dnrV* and the C-terminal part of the *dnrU* (Δ *dnrU*) genes
15 (complementary strand to the coding strand).

Fig. 2 (a-d) illustrate the construction of the plasmid pIS284 described in Example 1. This plasmid contains the 2.9 kb fragment encompassing the *doxA*, the *dnrV* and the C-terminal part of the *dnrU* genes, obtained from the recombinant plasmid pIS70, under the control of the strong promoter *ermE** together with a DNA fragment
20 of 2.3 Kb including the *drrA* and *drrB* resistance genes obtained from the plasmid pWHM603 (P. Guilfoile and C.R. Hutchinson, Proc. Natl. Acad. Sci. USA 88:8553, 1991) subcloned into the plasmid pWHM3.

Fig. 3 (a-c) illustrate the construction of the plasmid pIS287 described in Example 2. Said plasmid was constructed by insertion of the 2.9 kb *BamHI-HindIII*
25 fragment containing the *doxA* formerly, *dxrA*), *dnrV* (formerly *dnr-ORF10*) and the C-terminal part of the *dnrU* (Δ *dnrU*, formerly, *dnr-ORF9*) genes, obtained from the recombinant plasmid pIS70 (WO 96/727014), under the control of the strong promoter *ermE** together with the 2.3 kb *XbaI-HindIII* DNA fragment containing the *drrA* and *drrB*

resistance genes and the 3.9 kb *EcoRI-HindIII* fragment containing the *drrC* resistance gene into the plasmid pWHM3.

The maps shown in Figs. 1,2 and 3 do not necessarily provide an exhaustive listing of all restriction sites present in the DNA fragments. However, the reported sites
5 are sufficient for an unambiguous recognition of the DNA segments.

Restriction sites abbreviations: *Ap*, apramycin; *tsr*, thiostrepton, *amp*, ampicillin; *B*, *BamHI*; *G*, *BglII*; *N*, *NotI*; *K*, *KpnI*; *E*, *EcoRI*; *H*, *HindIII*; *P*, *PstI*; *S*, *SphI*; *X*, *XbaI*, *L*, *BglI*; *T*, *SstI*.

Detailed description of the invention.

10 The present invention provides a DNA molecule in which a DNA region or fragment containing the gene encoding a daunorubicin C-14 hydroxylase is joined to a DNA region or fragment containing one, two or three different genes selected from the group consisting of *drrA*, *drrB*, *drrC* genes encoding proteins conferring to the host cells resistance to daunorubicin and doxorubicin.

15 The DNA region containing the gene encoding a daunorubicin C-14 hydroxylase is preferably the 2.9 kb DNA region obtained from the recombinant plasmid pIS70 described in the patent WO 96/27014 by digestion with *BamHI-HindIII* enzymes. This fragment contains the *doxA* gene, encoding the C-14 hydroxylase. Daunorubicin C-14 hydroxylase converts daunorubicin to doxorubicin. The 2.9 kb DNA fragment also
20 comprises the *dnrV* gene between the *NotI-KpnI* sites and a *NotI-SphI* fragment containing the C-terminal part of the *dnrU* (Δ *dnrU*) gene.

Preferably, this 2.9 kb DNA fragment encoding a daunorubicin C-14 hydroxylase was ligated to both the 2.3 kb *XbaI-HindIII* DNA fragment containing the *drrA* and *drrB* resistance genes obtained from the plasmid pWHM603 and the 3.9 kb *EcoRI-HindIII*
25 fragment containing the *drrC* gene obtained from the plasmid pWHM264; in another preferred embodiment, the 2.9 kb DNA fragment is ligated to the 2.3 kb *XbaI - HindIII* DNA fragment only.

All the DNA molecules encoding a daunorubicin C-14 hydroxylase described in WO 96/27014 may be employed in the present invention.

In particular the DNA molecule of the present invention may comprise all of the 2.9 kb DNA fragment or only a part of the fragment, at least 1.2 kb in length corresponding to the *KpnI-BamHI* fragment containing the DNA molecule of *doxA*, encoding a daunorubicin C-14 hydroxylase, which converts daunorubicin to doxorubicin.

5 This DNA molecule consists essentially of the sequence reported in the patent application WO 96/27014, which sequence is referred to as the "*dxrA*" sequence. Also, the deduced amino acid sequence of the daunorubicin C-14 hydroxylase is shown in that patent application.

The DNA molecule of the present invention may comprise at least 2247 nt of the

10 2.3 kb *XbaI-HindIII* DNA fragment containing the *drrA* and *drrB* genes encoding proteins conferring to host cells resistance to daunorubicin and doxorubicin.

The DNA molecule of the invention may comprise all or part of the 3.9 kb *EcoRI-HindIII* fragment containing the *drrC* resistance gene, at least 2.5 kb in length corresponding to the *SstI-SphI* fragment containing the DNA molecule of *drrC*, encoding

15 a protein conferring to host cells resistance to daunorubicin and doxorubicin.

The present invention also includes DNA comprising genes conferring resistance to doxorubicin and daunorubicin having a sequence at least 80% identical to the sequences of the *drrA* and *drrB* genes (Guilfoile and Hutchinson, Proc.Natl.Acad.Sci.USA 88:8553, 1991) and or *drrC* gene (Lomovskaya et al.,

20 J.Bacteriol.178:3238, 1996).

The DNA molecule of the invention may be ligated to a heterologous transcriptional control sequence in the correct fashion or cloned into a vector at a restriction site appropriately located near a transcriptional control sequence in the vector. Preferably the transcription of the different genes may be coordinated by a

25 common strong promoter such as *ermE** (Bibb et al., Molec. Microbiol. 14:533, 1994).

The DNA molecule of the invention may be ligated into any autonomously replicating and/or integrating agent comprising a DNA molecule to which one or more additional DNA segments can be added. Typically, however, the vector is a plasmid. A

preferred plasmid is the high-copy number plasmid pWHM3 or pIJ702 (Katz et al., J. Gen. Microbiol. 129:2703, 1983). Other suitable plasmids are pIJ680 (Hopwood et al., Genetic Manipulation of *Streptomyces*. A laboratory Manual, John Innes Foundation, Norwich, UK, 1985) and pWHM601 (Guilfoile and Hutchinson, Proc. Natl. Acad. Sci. USA 88:8553, 1991).

Any suitable technique may be used to insert the DNA into the vector. Insertion can be achieved by ligating the DNA into a linearized vector at an appropriate restriction site. For this, direct combination of sticky or blunt ends, homopolymer tailing, or the use of a linker or adapter molecule may be employed.

The recombinant vector may be used to transform a suitable host cells that do not or do produce anthracyclines.

The host cells may be ones that are daunorubicin or doxorubicin sensitive, i.e., cannot grow in the presence of a certain amount of daunorubicin or doxorubicin, or that are daunorubicin or doxorubicin resistant. In any case the resulting recombinant clones obtained by transformation with the new recombinant vectors of the invention show higher level of resistance to daunorubicin and doxorubicin than the parental host. The level of doxorubicin resistance in recombinant *S. lividans* is much higher than the level observed in anthracycline producing strains *S. peucetius* ATCC 29050 and ATCC 27952.

The host may be a microorganism such as a bacterium. Strains of Actinomycetes, in particular strains of *S. lividans* and other strains of *Streptomyces* species that do not produce anthracyclines may be transformed. *S. lividans* TK 23 is a more suitable host in comparison to the *S. peucetius dnrN* mutant transformed with the recombinant plasmid pIS70 containing the *dxrA* gene used for daunorubicin to doxorubicin bioconversion (WO 96/27014).

The recombinant vectors of the invention may also be used to transform a suitable host cell which produces daunorubicin, in order to enhance the conversion of daunorubicin to doxorubicin.

S. peucetius ATCC 29050 and ATCC27952 strains including their mutants that produce

anthracyclines may therefore be transformed. In particular *S. peucetius* strain WMH1654, a mutant strain obtained from *S. peucetius* ATCC 29050 and deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, USA, under the accession number ATCC55936 may be used.

5 Transformants of *Streptomyces* strains are typically obtained by protoplast transformation.

The invention includes processes for improving doxorubicin production by conversion of daunorubicin, which processes comprise a bioconversion process of added daunorubicin into doxorubicin in hosts which do not produce anthracyclines and
10 a fermentation process for producing doxorubicin in hosts which directly produce daunorubicin.

Bioconversion process of daunorubicin to doxorubicin.

This process comprises:

- 1) culturing the recombinant host cells not producing daunorubicin transformed with the
15 vectors of the invention to which daunorubicin is added and
- 2) isolating doxorubicin from the culture.

In this process the recombinant strain may be cultured at temperatures from 20°C to 40°C, for example from 24°C to 37°C. The daunorubicin is added to the culture medium from 24 to 96 hours of the growth phase. The culture is preferably carried out
20 with shaking. The duration of the culture in the presence of daunorubicin may be from 12 to 72 hours. The concentration of daunorubicin in the culture may be from 20 to 1000 mcg/ml; for example from 100 to 400 mcg/ml.

Doxorubicin production by fermentation.

This process comprises:

- 25 1) culturing recombinant daunorubicin-producing host cells transformed with the vectors of the invention and
- 2) isolating doxorubicin from the culture.

In this process the recombinant strain may be cultured at temperature from 20°C

to 40°C; for example from 26°C to 34°C. The culture is carried out with shaking. The duration of the culture may be from 72 to 168 hours.

Materials and Methods

- 5 Bacterial strains and plasmids: *E. coli* strain DH5 α , which is sensitive to ampicillin and apramycin is used for subcloning DNA fragments. The host *S. lividans* TK23 was obtained from D. A. Hopwood (John Innes Institute, Norwich, United Kingdom) and the host *S. peuceitius* WMH1654 is a mutant strain obtained from *S. peuceitius* ATCC 29050 and has been deposited at the American Type Culture Collection, 10801 University
10 Boulevard, Manassas, Virginia 20110-2209, USA, under the accession number ATCC55936.

The plasmid cloning vectors are pGem-7Zf(+) and related plasmids (Promega, Madison, WI), pIJ4070 (D. A. Hopwood) and the *E. coli-Streptomyces* shuttle vector pWHM3 (Vara et al., J. Bacteriol. 171:5872, 1989).

15

Media and buffer: *E. coli* strain DH5 α is maintained on LB agar (Sambrook et al., *Molecular Cloning. A Laboratory Manual*, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989). When selecting for transformants, ampicillin or apramycin are added at concentrations of 100 micrograms/ml.

- 20 *S. lividans* TK23 and *S. peuceitius* WMH1654 are maintained on R2YE (Hopwood et al., *Genetic Manipulation of Streptomyces. A Laboratory Manual*, John Innes Foundation, Norwich, UK, 1985) and ISP4 (Difco, Detroit, MI) agar media, respectively. When selecting for transformants, the plates are overlaid with soft agar containing thioestrepton at a concentration of 50 micrograms/ml.

25

Subcloning DNA fragments: DNA samples are digested with appropriate restriction enzymes and separated on agarose gels by standard methods (Sambrook et al., *Molecular Cloning. A Laboratory Manual*, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989). Agarose slices containing DNA fragments of interest are

excised from a gel and the DNA is isolated from these slices using the GENE CLEAN device (Bio101, La Jolla, CA) or an equivalent. The isolated DNA fragments are subcloned using standard techniques (Sambrook et al., *Molecular Cloning. A Laboratory Manual*, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989) into *E. coli* for routine manipulations, and *E. coli-Streptomyces* shuttle vectors or *Streptomyces* vectors for expression experiments.

Transformation of *Streptomyces* species and *E. coli*: Competent cells of *E. coli* are prepared by the calcium chloride method (Sambrook et al., *Molecular Cloning. A Laboratory Manual*, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989) and transformed by standard techniques (Sambrook et al., *Molecular Cloning. A Laboratory Manual*, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989). *S. lividans* TK23 is grown in liquid R2YE medium (Hopwood et al., *Genetic Manipulation of Streptomyces. A Laboratory Manual*, John Innes Foundation, Norwich, UK, 1985) and harvested after 48 hr. The mycelial pellet is washed twice with 10.3% (wt/vol) sucrose solution and used to prepare protoplasts according to the method outlined in the Hopwood manual (Hopwood et al., *Genetic Manipulation of Streptomyces. A Laboratory Manual*, John Innes Foundation, Norwich, UK, 1985). The protoplast pellet is suspended in about 300 microlitres of P buffer (Hopwood et al., *Genetic Manipulation of Streptomyces. A Laboratory Manual*, John Innes Foundation, Norwich, UK, 1985) and 50 microlitres aliquot of this suspension is used for each transformation. Protoplasts are transformed with plasmid DNA according to the small scale transformation method of Hopwood et al. (*Genetic Manipulation of Streptomyces. A Laboratory Manual*, John Innes Foundation, Norwich, UK, 1985), Stutzman-Engwall and Hutchinson (Proc. Natl. Acad. Sci. USA. 86:3135, 1988) or Otten et al. (J. Bacteriol. 172: 3427, 1990). After 17 hr of regeneration on R2YE medium at 30°C, the plates are overlaid with 200 micrograms/ml of thiostrepton and allowed to grow at 30°C until sporulated.

Evaluation of daunorubicin and doxorubicin resistance level: The level of resistance is expressed as Minimal Inhibitory Concentration (MIC) and is determined by the standard two-fold dilution method using R2YE medium. The strains are cultured in slants of R2YE medium and incubated at 28°C for 8-10 days. Recombinant strains are grown in the same medium added with 20 micrograms/ml of thiostrepton. Bacterial cultures containing approximately 10^6 - 10^7 viable cells/ml are prepared from cultures grown at 28°C at 280 rpm for 48 hours in Tryptic Soy Broth (Difco). The cultures are homogenized by glass beads. One loopful of the homogenized cultures is inoculated on the agar plates containing different concentrations of daunorubicin and doxorubicin from 0.39 to 800 micrograms/ml. The agar plates are incubated at 30°C for 7 days and the MICs are determined as the lowest concentrations that prevent visible growth.

Daunorubicin to Doxorubicin bioconversion: *S. lividans* TK23 transformants harboring a plasmid of the invention are inoculated into 25 ml of liquid R2YE medium with 40 micrograms/ml of thiostrepton. Cultures are grown in 300 ml Erlenmeyer flasks and incubated on a rotary shaker at 280 rpm at 30 C°. After 2 days of growth, 2.5 ml of this culture are transferred to 25 ml of APM production medium: ((g/l) glucose (60), yeast extract (8), malt extract (20), NaCl (2), 3-(morpholino)propanesulfonic acid (MOPS sodium salt) (15), $MgSO_4 \cdot 7H_2O$ (0.2), $FeSO_4 \cdot 7H_2O$ (0.01), $ZnSO_4 \cdot 7H_2O$ (0.01), supplemented with 20 micrograms/ml of thiostrepton. 400 micrograms/ml of daunorubicin are added at 48 hr. of the growth phase. Cultures are grown in 300 ml Erlenmeyer flasks and incubated on a rotary shaker at 280 rpm at 30 C° for 72 hr. Each culture is acidified with 25 milligrams/ml of oxalic acid and after incubation at 30°C on a rotary shaker at 280 rpm for 30 min. is extracted with an equal volume of acetonitrile:methanol (1:1) at 30°C and 300 rpm for 2 hr. The extract is filtered and the filtrate is analyzed by reversed-phase high pressure liquid chromatography (RP-HPLC). RP-HPLC is performed by using a Vydac C_{18} column (4.6 x 250 millimeters; 5

micrometers particle size) at a flow rate of 0.385 ml/min. Mobile phase A is 0.2% trifluoroacetic acid (TFA, from Pierce Chemical Co.) in H₂O and mobile phase B is 0.078% TFA in acetonitrile (from J.T.Baker Chemical Co.). Elution is performed with a linear gradient from 20 to 60% phase B in phase A in 33 minutes and monitored with a diode array detector set at 488 nm (bandwidth 12 micrometers). Daunorubicin and doxorubicin (10 micrograms/ml in methanol) are used as external standards to quantitate the amount of these metabolites isolated from the cultures.

Doxorubicin production: The *S. peucetius* WMH1654 mutant is transformed with a plasmid of the invention. Transformants are inoculated into 25 ml of R2YE medium supplemented with 20 micrograms/ml thiostrepton. Cultures are grown in 300 ml Erlenmeyer flasks on a rotary shaker at 280 rpm at 30°C. After 2 days of growth, 2.5 ml of this culture are transferred to 25 ml of APM medium supplemented with 20 micrograms/ml thiostrepton. Cultures are grown in 300 ml Erlenmeyer flasks on a rotary shaker at 280 rpm at 28°C for 96 - 120 hours. Each culture is acidified with 25 milligrams/ml of oxalic acid and, after 45 min. incubation at 30°C on a rotary shaker at 280 rpm, is extracted with an equal volume of acetonitrile:methanol (1:1) at 30°C and 300 rpm for 2 hr. The extract is filtered and the filtrate is analyzed by RP-HPLC following the same method used to analyze the bioconversion products.

20

Example 1

Example 1 (Fig. 1 (a-c) and Fig. 2 (a-d)).

In order to remove a non-essential region, the plasmid pIS70 (WO96/27014) is before digested *EcoRI-HindIII* and the 3.5 kb fragment is subcloned into the same sites of the multiple cloning site sequence of the plasmid pGEM-7Zf (+) (Promega, Madison-WI USA) to obtain another *BamHI* restriction site. The new plasmid pGendoxAUV was *BamHI* digested and the fragment, now reduced to 2.9 kb, was transferred into the

plasmid pIJ4070 (from the John Innes Institute, Norwich, UK) under the control of strong promoter *ermE*^{*}. This new plasmid, named p7doxAUV, was digested *Bgl*III and the fragment inserted into the plasmid pWHM3 (J.Vara et al., J. Bacteriol. 171:5872-5881, 1989) to obtain the plasmid pIS156 (fig. 1c).

- 5 The 2.3 kb *Bgl*III fragment containing the *drrA* and *drrB* resistance genes is transferred after blunt ending from the plasmid pWHM603 into the *Sma*I site of the plasmid pBluescript II SK + (Stratagene) to obtain the plasmid p*drrAB* and an *Xba*I-*Hind*III fragment is transferred from p*drrAB* into the vector pIJ4070 to obtain pIS278. Afterwards, pIS278 is digested with *Eco*RI-*Xba*I and inserted into the *Eco*RI-*Xba*I
- 10 plasmid pWHM3 to obtain the plasmid pIS281. This plasmid is digested with *Xba*I and the *Xba*I fragment of plasmid pIS156 is inserted to obtain the plasmid pIS284.

Example 2

15

- Construction of the plasmid pIS287 (Fig.3 (a-c)): The *drrC* resistance gene contained in the plasmid pWHM264 is excised by *Eco*RI-*Hind*III digestion and inserted into the plasmid pIJ4070 to obtain the plasmid pIS282. From this plasmid, the *drrC* resistance gene is transferred as a *Bgl*III fragment to pIS252 (this plasmid is a modified form of
- 20 pWHM3 containing an extra *Bgl*III site close to the *Eco*RI site) to obtain the plasmid pIS285. pIS285 is *Eco*RI digested and ligated with the 5.5 kb DNA fragment excised from plasmid pIS284 to obtain the plasmid pIS287.

Example 3

- 25 Resistance of the above recombinant plasmids to doxorubicin: The level of resistance to daunorubicin and doxorubicin of *S. lividans* TK23 transformed with the recombinant plasmids pIS70, pIS284 or pIS287 in comparison with *S. lividans* TK23, *S. lividans* TK23 transformed with the vector pWHM3 and the anthracycline producing *S. peuceitius* ATCC 29050 and ATCC 27952 strains is determined as MICs on R2YE

medium following the procedure described in Materials and Methods. The maximum level of daunorubicin and doxorubicin resistance is obtained with the plasmid pIS287 containing the *drmA*, *drmB* and *drmC* resistance genes. The level of doxorubicin resistance was increased 64 times also with the plasmid containing only the *drmA* and
 5 *drmB*.resistance genes (Table 1).

Table 1. Resistance of recombinant strains to doxorubicin.

Strain	MIC for doxorubicin (micrograms/ml)
<i>S. peuceetius</i> ATCC 29050	12.5
10 <i>S. peuceetius</i> ATCC 27952	12.5
<i>S. lividans</i> TK23	12.5
<i>S. lividans</i> TK23(pWHM3)	12.5
<i>S. lividans</i> TK23(pIS284)	800
<i>S. lividans</i> TK23(pIS287)	>800

15

Example 4

Bioconversion of added daunorubicin to doxorubicin in *S. lividans* TK23 transformed with plasmids containing the *doxA* daunorubicin C-14 hydroxylase gene together with
 20 different resistance genes: The pIS70, pIS284 or pIS287 plasmids are introduced into *S. I ividans* TK23 by transformation with selection for thiostrepton resistance, according to the procedures described in the Materials and Methods section. The resulting *S. lividans* TK23(pIS70), *S. lividans* TK23(pIS284) and *S. lividans* TK23(pIS287) transformants are tested for the ability to bioconvert a high level (400 micrograms/ml)
 25 of daunorubicin to doxorubicin using the APM medium as described above. *S. lividans* TK23(pIS70) transformants can convert up to 11.5% of added daunorubicin to doxorubicin (Table 2). *S. lividans* TK23(pIS284) and *S. lividans* TK23(pIS287) transformants can convert up to 73.5% of added daunorubicin to doxorubicin (Table 2).

Table 2. Bioconversion of daunorubicin to doxorubicin by *S. lividans* strains.

Strain	Anthracycline (micrograms/ml)		
	DOX	DNR	13-dihydroDNR
5 <i>S. lividans</i> TK23(pIS70) (control)	46	250	70
<i>S. lividans</i> TK23(pIS284)	294	33	21
<i>S. lividans</i> TK23(pIS287)	288	24	35

10 Example 5

Doxorubicin production in the *S. peuceitius* WMH1654 *dnrX* mutant transformed with plasmids containing the *doxA* daunorubicin C-14 hydroxylase gene together with different resistance genes: The pIS284 and pIS287 plasmids are introduced into *S.*

15 *peuceitius* WMH1654 *dnrX* mutant strain by protoplasts transformation with selection for thiostrepton resistance, according to the procedures described in the Materials and Methods section. The resulting *S. peuceitius* transformants are fermented and the fermentation broths analyzed according to the method previously described. *S.*

20 *peuceitius* WMH1654(pIS284) produced up to 81 micrograms/ml of doxorubicin and up to 18 micrograms/ml of daunorubicin after a 120 hr fermentation (Table 3). *S. peuceitius* WMH1654(pIS287) produced up to 92 micrograms/ml of doxorubicin and no detectable amount of daunorubicin (Table 3).

Table 3. Doxorubicin production by *S. peucetius* WMH1654 *dnrX* strains.

Strain	Anthracycline (micrograms/ml)		
	DOX	DNR	13-dihydroDNR
<i>S. peucetius</i> WMH1654	41	35	18
5 <i>S. peucetius</i> WMH1654(pIS284)	81	18	6
<i>S. peucetius</i> WMH1654(pIS287)	92	0	0

SEQ ID.1

1 GGATCCGCAC CGGGTACACG GCACGGGACC GCCCACCGCG CGGTGCGCGG
5
51 TGGGCGGTCC CGTGCCGGTC GCGGCCGGCG GATCAGCGCA GCCAGACGGG
10
101 CAGTTCGGTG AGCCGCGCCG TCTGGGCCCC CTCCGGCAC CACCGCAACT
151 CGTCGTACGG CACGGCCAGT CGGGCCTCGG GGAACCTGCT GCGCAGTACG
15
201 CCGATCATCG TGC GCGACTC CAGCTGGGCG AGCTGCTCCC CGATGCAGTA
251 GTGCGGCCCG TCGCCGAAGG TGAGCCGCCG CCACGAGGGA CGGTCCGGGT
20
301 GGAAGGCGTG CGGGGCGTCG TGATGGCGGC CGTCGGTGTT GGTGCCCTCG
351 ATGTCCACCA GCACCGGCGC TCCGCGGGGC AGCCGGACGC CGCCGATGGT
25
401 CACCTCCGTG GCAGCGAACC TCCACAACGT GTAGGGCACC GGCGGGTGGT
30
451 AGCGCAGCGC CTCCTCCACG AACCGGGAGA CGGCGTCCTC GTCGGCATCC
501 GCCGCGAGGC GGCCCGCCAG GACCTCCGCG AGCAGGAAGC CCAGGAAGGA
35
551 GCCGGTGGTG TCGTGCCGG CGAAGATGAG CCCGGTGATC ATGTAGACGA
40
601 GCTGGTCGTC GGAGACCGAG CCGAACTCGG CCTGCGCGCG CTCGTACAGC
651 ACGCGGGTCA TGGTCGGGGT GTCGTTCCGC CGGGCTGAGT GCACGGCTTC
45
701 GAGGAGCAGG CTCTCCAGGG CCGAGGTGTC CGGCACGCCC CCGGCAGGGT
751 CCGTGCCGTC ACCCCCGCCG CTCTGCGGGC CGCCGAGGCC GAGTGCCTTG
50
801 AGAACGCTGA CGGCCTCGCG GGCCATCGCC GGATCGGTGA CCGGCACACC

851 GAGCAGCTCG CAGATGACCA ACAGCGGGAA GTGGTACGCG AAGCCGCCGA
5
901 TCAGCTCGGC CGGTTTGCCC GACCGGCCGG AGGCGTCGGC GAGTTCGGTG
951 AGCAGCCGGC CGGCGATCGC GGCGATGCGA TCCGTCCGCT CGGCCAGCCG
10
1001 GCGCGGGTTG AACGCAGGTG CGTGGATGCG GCGCAGGCGC CGGTGGGCCT
1051 CGCCGTCCAC GGCGATGAGC GTGAACGGAC GCAGCTCCGG AACGGGGATG
15
1101 TCGAGACCGT CGTCCACCCC CCGCCAGGCG GCGGGGGCGA GGTCGGGGTC
1151 CTTACGAAC CGGGGATCGG CCAGCACCTC GCGGGCGAGG GCGTCATCGG
20
1201 TGATGACCCA GGCGGGTCCG CCCGCGGGGG CGTTCACCTC GACGACCGGG
25
1251 CCCGCCTCCC GGAAGGCGTC GTGCACCTCG GGCTTGCGCT GCATGGTCAT
1301 CATGGGACAC GCGAACGGGT CGACGGCCAC CCGGGGCGCC TCGCCGCTCA
30
1351 CGAGGCACCG CCCGCCGCCG CGGGGTACCC CTCCCGCAGT TCGACCACCG
35
1401 AGAAGCCGGC CCCGTGCGGG TCGAGCAGGT CCGCCCGCCG CCCCTGGGC
1451 GTGTGGCGG GCTCGTTCTC GACGGAGCCG CCGAGTTCAA CGGCGCGCCG
40
1501 GACCGTCGCG TCGCAGTCGT GCACGGCGAA CAGCACGGCC CAGTGCGGCC
1551 GTACCGCGCC GGTGACGCC AGCTCCTGGG TGCCGGCGAC CGGTGTGTCA
45
1601 CCGATGTGCC AGACCGGGTC GGTGACGCC TTCAGTCCGG TGTCGGCCGG
50
1651 AGCCAGGCCG AGGGTCGCCG GGTAAGTC CCGGGCGGCC CCGATGCCGT

1701 CGGTCACCAG CTCGACCCAG CCGACCGAGC CGGGCACGCC CGTCACCTCC
5
1751 GCGCCCTCCA TGA CTCCCTT GCGCCAGACC GCGAACGCGG CCCC GGCGGG
1801 GTCGGCGAAG ACCGCCATCC GGCCGAGGCC GAGGACGTCC ATCGGAGTCA
10
1851 TGATGACCTC GCCGCCCGCC GTCTCGACCC GCTTGGTCAG TCGTCCGGCG
1901 TCGTCGGTGG CGAAGTACAC GGTCCAGATG GCCGGCATGC CGTGCTGGTC
15
1951 GTTCCCGGGC CCGTACGGCC GGTGGTAGGG GGTGTGATC TGGTGGCGGG
20
2001 CGACCGCGGC GACCAGCTTC CCGTCGGAGC TGAACGTCGT GTATCCCCCG
2051 GCGCCCGGGT CGCTGACCAC GGTGGCGGTC CAGCCGAACA GGCCGGTGTA
25
2101 GAAGTCGGCC GAGGCGGCGA CATCGGGCGA ACCGAGGTCG AACCATGCGG
2151 GGGCGCCGGG CGCGAACCTG GTCACGAATC GTTCCTTTTCG ATGGATCGGC
30
2201 ACACGAGCGT CTGCGCTCGC GGATGAGACG GACATCTCGC GGATGAGACG
35
2251 GACATGCGGG CGGGGCGGGC CGCCGCCGTC AGTGCGCGGT GTCGCCGACG
2301 GCGGCCGCGC CGGCCTCCA GAGCTTCGCC GCGAGGCCGG CGTCGGCGGT
40
2351 CGGGCCGCTC ACCGGGGACA GCCGCCGGTC GCTGTAGTAG CCGCCCGTGG
2401 TCAACTCCTC GGCCGGCGCG GACGCCAGCC ACACGAGGGT GTCGGCGCCC
45
2451 TTCGCCGCGG AGCGCAGGAA GGGGTTGAAC CGGAAGTAGG ACGAGGCGAC
50
2501 CGTGCCCCGT CCGATGCGGG TCGGACCTC ACCGGGGTGA TAGCTGACCG

2551 CCAGCACGTC CGGCCAGCGC CTGGCGGCCT CCGCCGCGGT CATGATGTTG
5 2601 GCCTGTTTGG ACGTGCCGTA CGCCTGGCCG GCGCTGTAGC GGTGACGGTC
2651 GCCGTTGAGG TCGTCCGGGT CGATCCGGCC CTGGGTGTAC GCGTCGGACG
10 2701 AGGTGAGGAT CAGCCGCCCC CCCGCGAGCC GCTCCCGCAG CAGCCGTGCC
2751 AGCAGGAAGC CTGCGAGGTG ATTGACCTGG ATGGTGGCCT CGAACCCGTC
15 2801 CTGGGTCGTG GTGCGCGACC AGAACATGCC GCCGGCGTTG CTGGCCATGA
20 2851 CATCGATGCG CGGGTACCGG

CLAIMS

1. A DNA molecule comprising a DNA region containing a gene *doxA* encoding daunorubicin 14-hydroxylase and a DNA region containing at least one gene conferring daunorubicin and doxorubicin resistance.
2. A DNA molecule according to claim 1, further comprising a strong promoter.
3. A DNA molecule according to claim 2, wherein said strong promoter is *ermE**.
4. A DNA molecule according to claim 1, wherein said gene conferring daunorubicin and doxorubicin resistance is selected from the group consisting of *drrA*, *drrB* and *drrC* genes and any mixtures thereof.
5. A DNA molecule according to claim 4, wherein said genes conferring daunorubicin and doxorubicin resistance are *drrA* and *drrB* genes.
6. The DNA molecule according to claim 4, wherein said genes conferring daunorubicin and doxorubicin resistance are *drrA*, *drrB* and *drrC* genes.
7. The DNA molecule according to claim 1, wherein the region containing the gene *doxA* encoding daunorubicin 14-hydroxylase is 2.9 kb in length.
8. The DNA molecule according to claim 7, wherein the fragment containing the gene *doxA* corresponds to the *KpnI-BamHI* fragment containing the *doxA* nucleotide sequence.
9. The DNA molecule according to claim 5, wherein said region containing said

drrA and *drrB* genes is a 2.3 kb *XbaI-HindIII* DNA fragment.

10. The DNA molecule according to claim 1, wherein said genes conferring daunorubicin and doxorubicin resistance are at least 80% identical to genes selected from the group consisting of *drrA*, *drrB* and *drrC* genes.

11. A vector containing a DNA molecule according to claim 1.

12. A vector according to claim 11 wherein said vector is a plasmid.

13. A plasmid according to claim 12, wherein said plasmid is selected from the group consisting of pIS284 and pIS287.

14. A host cell transformed or transfected with a vector according to claim 11.

15. The host cell according to claim 14, wherein said host cell does not produce daunorubicin.

16. The host cell according to claim 14, wherein said host cell is a bacterial cell which produces daunorubicin.

17. The recombinant host cell according to claim 14, wherein said host cell is a *Streptomyces* cell .

18. A process for bioconverting daunorubicin into doxorubicin, comprising the steps of:

culturing a recombinant host cell in a culture medium containing daunorubicin, wherein said host cell contains a DNA molecule comprising a DNA

region containing a gene *doxA* encoding daunorubicin 14-hydroxylase and a DNA region containing at least one gene conferring daunorubicin and doxorubicin resistance, wherein said host cell does not produce daunorubicin, and

isolating any resulting doxorubicin from the culture medium.

19. A process for producing doxorubicin by fermentation, comprising the steps of:
culturing a recombinant host cell in a culture medium, wherein said host cell contains a DNA molecule comprising a DNA region containing a gene *doxA* encoding daunorubicin 14-hydroxylase and a DNA region containing one or more genes conferring daunorubicin and doxorubicin resistance, wherein said host cell is a bacterial cell which produces daunorubicin, and

isolating any resulting doxorubicin from the culture medium.




Fig. 1a




Fig. 1b




Fig. 1c




Fig. 2a




Fig. 2b




Fig. 2c




Fig. 2d




Fig. 3a




Fig. 3b

10/10




Fig. 3c

1/2
SEQUENCE LISTING

<110> PHARMACIA & UPJOHN S.P.A.

<120> PROCESS FOR PREPARING DOXORUBICIN

<130> 1615-9003

<140> PCT/UNKNOWN

<141> 1999-04-22

<150> 09/065,606

<151> 1998-04-24

<160> 1

<170> PatentIn Ver. 2.0

<210> 1

<211> 2870

<212> DNA

<213> Streptomyces peucetius

<220>

<221> misc feature

<222> Complement((1)..(2870))

<223> Complementary strand to the coding strand

<400> 1

```

ggatccgcac cgggtacacg gcacgggacc gccaccgcg cgggtgcgcg tgggocggctc 60
cgtgccggtc gcggccggcg gatcagcgca gccagacggg cagttcgggtg agccgcgccc 120
tctgggcccc cttccggcac caccgcaact cgtcgtacgg cacggccagt cgggcctcgg 180
ggaacctgct gcgcagtagc ccgatcatcg tgcgcgactc cagctgggcg agctgctccc 240
cgatgcagta gtgcggcccc tcgccgaagg tgagccgcgg ccacgagggg cggtcggggt 300
ggaaggcgtg cggggcgctg tgatggcggc cgtcgggtgt ggtgccctcg atgtccacca 360
gcaccggcgc tccgcggggc agccggacgc cgcgatggt cacctccgtg gcagcgaacc 420
tccacaacgt gtagggcacc ggccgggtgt agcgcagcgc ctctccacg aaccgggaga 480
cggcgtcctc gtccggcatc gccgcgaggc ggcccgcag gacctccgcg agcaggaagc 540
ccaggaagga gccggtggtg tcgtggccgg cgaagatgag cccggtgatc atgtagacga 600
gctggtcgtc ggagaccgag ccgaactcgg cctgcgcgcg ctcgtacagc acgcccgtca 660
tggtcggggt gtctgtccgc cgggctgagt gcacggcttc gaggagcagg ctctccaggg 720
ccgaggtgtc cggcacgccc ccggcagggt ccgtgcctc accccgcgg ctctccgggc 780
cgccgaggcc gactgccttg agaacgctga cggcctcgcg ggccatcgcc ggatcgggta 840
ccggcacacc gacgagctcg cagatgacca acagcgggaa gtggtacgcg aagccgcca 900
tcagctcggc cggtttgccc gaccggccgg aggcgtcggc gaggttcgggtg agcagccggc 960
cggcgatcgc ggcgatgcca tccgtccgct cggccagccg gcgcccgttg aacgcagggtg 1020
cgtggatgcg gcgcaggcgc cggtgggcct cgcctccac ggcgatgagc gtgaacggac 1080
gcagctccgg aacggggatg tcgagaccgt cgtocacccc ccgccaggcg gcgggggcca 1140
ggtcggggtc cttcacgaac cggggatcgg ccagcacctc gcgggcgagg gcgtcatcgg 1200
tgatgacca ggccgggtccg cccgcggggg cgttcacctc gacgaccggg cccgcctccc 1260
ggaaggcgtc gtgcacctcg ggcttgctgt gcatggtcat catgggacac gcgaacgggt 1320
cgacggccac ccggggcgcc tcgccgctca cgaggcaccg cccgcgcggc cgggggtacc 1380
ctcccgcagt tcgaccaccg agaagccggc cccgtgcggg tcgagcaggt ccgcccgccg 1440
ccccctgggc gtgtcggcgg gctcgttctc gacggagccg ccgagttcaa cggcgcgccc 1500
gaccgtcgcg tcgcagtcgt gcacggcgaa cagcacggcc cagtgcggcc gtaccgcgcc 1560
ggtgacgccc agctcctggg tgccggcgac cgggtgtgtca ccgatgtgcc agaccgggtc 1620
ggtgacgccc ttcagtcggg tgccggccgg agccaggccg agggtcgccg ggtagaagtc 1680
ccgggcggcc ccgatgccgt cggtcaccag ctccgaccag ccgaccgagc cgggcacgcc 1740
cgtcacctcc gcgccctcca tgactccctt gcgccagacc gcgaacgccc ccccgccggg 1800
gtcggcgaag accgccatcc ggccgaggcc gaggacgtcc atcggagtca tgatgacctc 1860
gccgcccgcc gtctcgaccc gcttggtcag tgcgtcggcg tcgtcgggtg cgaagtacac 1920
ggtccagatg gccggcatgc cgtgctggtc gttcccggc ccgtacggcc ggtggtaggg 1980

```

ggtgtcgatc	tggtggcggg	cgaccgcggc	gaccagcttc	ccgtcggagc	tgaacgtcgt	2040
gtatccccg	gcgcccgggt	cgctgaccac	ggtggcggtc	cagccgaaca	ggccgggtga	2100
gaagtccggc	gagggcggca	catcgggcga	accgaggtcg	aaccatgcgg	gggcgcggg	2160
cgcgaacctg	gtcacgaatc	gttcctttcg	atggatcggc	acacgagcgt	ctgcgctcgc	2220
ggatgagacg	gacatctcgc	ggatgagacg	gacatgcggg	cggggcgggc	cgccgccgtc	2280
agtgcgcggg	gtcgcgcgac	gcggccgcgc	cggcctccca	gagcttcgcc	gcgaggccgg	2340
cgtcggcggg	cgggccgctc	accggggaca	gccgcgggtc	gctgtagtag	ccgcccgtgg	2400
tcaactcctc	ggccggcgcg	gacgccagcc	acacgagggg	gtcggcgccc	ttcgccgcgg	2460
agcgcaggaa	ggggttgaac	cggaagtagg	acgagggcgc	cgtgccccgt	ccgatgcggg	2520
tgcggaacctc	accgggggtga	tagctgaccg	ccagcacgtc	cggccagcgc	ctggcggcct	2580
ccgcccgggt	catgatggtg	gcctgtttgg	acgtgocgta	cgccctggccg	gcgctgtagc	2640
ggtgacggtc	gccgttgagg	tcgtccgggt	cgatccggcc	ctgggtgtac	gcgtcggacg	2700
aggtgaggat	cagccgcccc	cccgcgagcc	gctcccgcag	cagccgtgcc	agcaggaagc	2760
ctgcgaggtg	attgacctgg	atggtggcct	cgaaccgcgc	ctgggtcgtg	gtgcgcgacc	2820
agaacatgcc	gccggcgttg	ctggccatga	catcgatgcg	cgggtaccgg		2870